Invitation to presentation of 3rd quarter report 2009 and Capital Markets Day

Please find an invitation to presentation of the Third Quarter 2009 Report and Capital Markets Day on Wednesday October 28th 2009:

Invitation
 
The 3Q presentation will be publicly available at www.photocure.com. It will be possible to follow the 3Q presentation through a live webcast.
 
Please register your attendance at Photocure ASA by Tuesday October 27th at 15:00 (CET).
Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).
 
Best regards,
Christian Fekete, CFO

Photocure ASA
Hoffsveien 48
0377 Oslo, Norway
Telephone: +47 22 06 22 10
Telefax:  +47 22 06 22 18
www.photocure.com
 
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
 
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing to leading pharmaceutical companies on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU and under priority review by FDA in the US. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.
 
For more information about Photocure, visit our website at www.photocure.com.

Photocure ASA